General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Featured news

  • 17-Nov-2011
    Novartis and collaborators discover new class of antimalarial compounds with potential to both prevent and treat malaria infections

    The discovery of a new class of dual-acting antimalarial compounds — the imidazolopiperazines (IZPs) — was published in the journal Science online, at the Science Express website today. The findings report on compounds that target both liver and blood infections, attacking the Plasmodium parasite at both stages in its reproduction cycle.

    Read the article

  • 17-Nov-2011
    The Novartis Malaria Initiative: lessons from a dramatic decade

    In 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria — without profit — for use by public health systems in developing countries.

    Read the article

  • 19-Sep-2011
    First Novartis company-wide health and well-being initiative

    Be Healthy aims to help Novartis Group Company associates around the world embrace healthy lifestyles by providing opportunities for them to take control of their personal health and help prevent future health issues.

    Read the article

  • 01-Sep-2011
    Fostering innovation among diverse young talent

    Future science and business leaders gathered at Novartis as some of the world’s most talented students met and exchanged ideas at the International BioCamp.

    Read the article

  • 22-Apr-2011
    The Novartis Malaria Initiative: lessons from a dramatic decade

    In 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria – without profit – for use by public health systems in developing countries.

    Read the article

  • 08-Apr-2011
    Stronger together: Novartis and Alcon creating the global leader in eye care

    Together, Novartis and Alcon will hold competitive positions in highly complementary product areas and create an even stronger global leader in the dynamic eye care sector.

    Read the article

  • 08-Apr-2011
    Novartis CEO Joseph Jimenez discusses Alcon merger

    We have a great opportunity to redefine and shape the eye care industry, with the ultimate goal of preventing blindness and treating diseases and disorders of the eye.

    Read the article

  • 08-Apr-2011
    Kevin Buehler, Division Head, Alcon, discusses merger with Novartis

    Completion of the merger with Novartis strengthens Alcon's position as the global leader in eye care and increases the breadth of our eye care portfolio.

    Read the article

The information in the feature stories on these pages was factually accurate on the date of publication. These feature stories remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.